- Tesaro (NASDAQ:TSRO) +59% on acquisition by Glaxo for $75.
- Global Blood Therapeutics (GBT) +41% as FDA accepts GBT's proposal for accelerated approval pathway for Voxelotor.
- Hudson Technologies (HDSN) +38% on amendments to credit facilities; achieves $35M in cash flow from operations for first nine months of 2018 with $45M in excess liquidity
- Atossa Genetics (ATOS) +35% as FDA has approved an “expanded access” of Atossa’s proprietary oral Endoxifen in the preoperative setting in a U.S. patient awaiting surgery for breast cancer.
- Clovis Oncology (CLVS) +26% on Tesaro deal.
- China Internet Nationwide Financial Services (CIFS) +20%.
- New Age Beverages (NBEV) +16%. on merger with Morinda.
- Karyopharm Therapeutics (KPTI) +15% on positive results from Phase 2b SADAL data for selinexor in patients with DLBCL.
- Oragenics (OGEN) +14%.
- CASI Pharmaceuticals (CASI) +12% as EVOMELA approved in China.
- Gemphire Therapeutics (GEMP) +12% on review of strategic alternatives and corporate update.
- Affimed N.V. (AFMD) +12%.
- vTv Therapeutics (VTVT) +13%.
- Crescent Point Energy (CPG) +11% as Alberta orders oil producers to cut production in face of price crisis.
- Tribune Media (TRCO) +10% as Nexstar confirms deal to buy for $46.50/share.
- China Ceramics (CCCL) +10%.
- CorMedix (CRMD) +9%.
- Immune Design (IMDZ) +6%. on reports increased overall response rate and longer progression free survival of patients with follicular lymphoma treated in a randomized trial with a combination regimen of G100 and Pembrolizumab.
- Stellar Biotechnologies (SBOT) +6%.
- Aeterna Zentaris (AEZS) +8%.
- Uxin (UXIN) +8%.
- Baozun (BZUN) +8%.
- iQIYI (IQ) +8% as initial purchasers exercise option to purchase additional $100M notes.
- ChinaNet Online Holdings (CNET) +8%.
- Fang Holdings (SFUN) +8% on Q3 result.
- Callon Petroleum (CPE) +7%.
- Vipshop Holdings (VIPS) +7%.